Study confirms benefit of combination therapy for Alzheimer's disease

September 22, 2008

First long-term study finds that treatment slows symptom progression, benefits last for years

Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Results from the first long-term study of the real-world use of Alzheimer's drugs, published by researchers from Massachusetts General Hospital in the July/September issue of Alzheimer Disease and Associated Disorders, support a level of effectiveness that may not be immediately apparent to patients or their family members.

"There has been the impression that these drugs only work for some patients and for a limited amount of time," says Alireza Atri, MD, PhD, of the MGH Department of Neurology, lead author of the current study. "One of the problems in judging these drugs has been that patients naturally continue to decline, which can make them think the drugs have stopped working. But our study, which has some unique strengths, indicates that treatment does have long-term benefit."

Two types of medications have received FDA approval for Alzheimer's treatment. Cholinesterase inhibitors have been available since the mid-1990s and act by inhibiting the breakdown of the neurotransmitter acetylcholine. The drug memantine, which received FDA approval in 2003, is the first of a second class of agents that modulate the actions of the amino acid glutamate and is often used in combination with cholinesterase inhibitors (CIs).

"Clinical trials that drug companies conduct for FDA approval only last six months and enroll patients according to very specific criteria," Atri explains. "Only large-population studies can really tell us how these drugs work for the full range of patients in real-life situations." The researchers were able to conduct such a study by analyzing data on patients treated at the MGH Memory Disorders Unit since 1990, including 144 who did not receive any pharmaceutical treatment, 122 treated with a CI alone and 116 who received both a CI and memantine. As part of their regular treatment, every six months patients received standardized assessments of both cognitive abilities and how well they carried out daily activities.

The results showed significant differences in the rate of symptom progression among all three groups - with the smallest level of decline in those receiving combination therapy. While there was an average of two and a half years' worth of data on the study participants, the researchers analyzed the information with a statistical model that predicted probable outcomes for up to four years. Although the model's projection of future benefits is conservative, it predicted that the longer patients kept receiving combination therapy, the smaller their rate of decline would become, suggesting that treatment might even protect brain cells from further damage, a possibility needing further investigation.

"Finding something that could actually modify the course of the disease is the Holy Grail of Alzheimer's treatment, but we really don't know if that is happening or what the mechanism behind these effects might be," Atri explains. "What we can say now is that providers should help patients understand that the benefits of these drugs are long term and may not be apparent in the first months of treatment. Even if a patient's symptoms get worse, that doesn't mean the drug isn't working, since the decline probably would have been much greater without therapy." Atri is an instructor in Neurology at Harvard Medical School (HMS) and associate director of the Center for Translational Cognitive Neuroscience at the Veterans Administration Hospital in Bedford, Mass.

John Growdon, MD - director of the MGH Memory Disorders Unit, professor of Neurology at HMS, and senior author of the paper - explains, "The results of this study should change the way we treat patients with Alzheimer's disease. Cholinesterase inhibitors are approved for use in mild to moderate dementia, while memantine has been approved for advanced dementia. But it looks like there is an advantage in prescribing both drugs as initial treatment."

Massachusetts General Hospital

Targeted Cancer Therapy (Current Clinical Oncology)
by Razelle Kurzrock (Editor), Maurie Markman (Editor)

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.

Randomized Trial to Evaluate Efficacy and Safety of Combination Budesonide and Formoterol and New FDA Mandate Regarding LABAs (Hospital Practice)
by JTE Multimedia

Original Article Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;6(17):2235–2254. PRACTICE PEARL Data from this randomized trial demonstrates that combination therapy with ICSs and LABAs increases FEV1 and improves asthma control and symptomatology compared with monotherapy alone in patients with moderate-to-severe asthma; recent FDA recommendations regarding use of LABAs must also be considered.

Antiepileptic Drugs: Combination Therapy and Interactions
by Jerzy Majkowski (Editor), Blaise F. D. Bourgeois (Editor), Philip N. Patsalos (Editor), Richard H. Mattson (Editor)

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and experimental data. The book consists of five sections covering the general concepts and advantages of combination therapies, the principles of drug interactions, the mechanisms of interactions, drug interactions in specific populations or in patients with co-morbid health conditions, and concludes with a look at the future directions for this field of research. The book will be of interest to all who...

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)
by Gary K. Schwartz (Editor)

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease (Lung Biology in Health and Disease)
by Richard Martin (Editor)

This book examines the therapies used for treatment of asthma and chronic obstructive pulmonary disease (COPD) separately and in combination, covering beta-agonists, theophylline, leukotriene modifiers, and anticholinergics. Highlights the importance of specific time dosing of medications! Revealing what medications to use and when to prescribe them, Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease · emphasizes anti-inflammatory therapy · compares and contrasts the side effects and efficacy of titration and various combinations · covers the steroid-sparing effect of combining inhaled corticosteroids and long-acting beta 2-agonists · includes over 1100 references that clarify outcomes among several different agents · details the mechanisms of inhaled...

Combination Therapy of AIDS (Milestones in Drug Therapy)
by Erik De Clercq (Editor), Anne-Mieke Vandamme (Editor)

An extensive assessment of combination therapy of AIDS. Main focus is put on the Highly Active Antiretroviral Therapy (HAART) but other therapies like salvage therapy are also discussed. The chapters cover efficacy, treatment, causes of treatment failure, clinical care, guidelines, pharmacology. The volume closes with an outlook on future perspectives.

Use of fixed-dose oral combinations: Advantages of early initiation of combination oral therapy include improved efficacy, fewer side effects, lower cost, ... better compliance. (Postgraduate Medicine)
by JTE Multimedia

Abstract: Early initiation of therapy to decelerate the decline in beta cell function and achieve low hemoglobin A 1c levels is advantageous in patients with type 2 diabetes. In this first of two articles on treatment of type 2 diabetes, the authors share their experience in optimizing therapy and advocate fixed-dose oral combinations because of lower cost, improved efficacy, better compliance, and fewer side effects. The second article (on page 15) looks at the use of injection therapy when oral therapy is not enough.

Original Publication Date: July 2006

Advances in Combination Therapy for Asthma and COPD
by Jan Lotvall (Editor)

Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion. A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combined therapies and additional considerations that arise from multi-agent programs are highlighted.

Combination Therapies (No. 1)
by E. Garaci (Editor), Allan L. Goldstein (Editor)

Combination Therapy in Urological Malignancy (Clinical Practice in Urology)
by Philip H. Smith (Editor)

This book emphasizes the importance of combining the skills of surgeon, radiotherapist and medical oncologist in the management of patients with malignant tumors of the urinary tract. After introductory chapters on radiation therapy, chemotherapy and immunotherapy, the individual urological tumors are discussed. The volume examines the increasing role of surgical preservations and reconstruction and the role played by clinical trials. Other factors such as quality of life and cost of treatment are also dealt with. The assessment of therapeutic possibilities is unique; no other volume is devoted to combination therapy as such in urological malignancy.